Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost
This article was originally published in The Pink Sheet & The Rose Sheet
French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.
You may also be interested in...
FDA assessing contamination of Rx and OTC H2 blocker ranitidine to determine steps it should take. The contaminant, NDMA, is dangerous when consumed in large quantities, but has been found in H2 blockers at levels that don't pose a risk, FDA says.
Sanofi says with Nasacort Allergy 24HR available at retailers nationwide and online, the firm withdrew its litigation against FDA, which appears to have slowed development of private-label equivalents.
The “Nonprescription Drug Product with an Additional Condition” for OTC use proposed rule would add to drug firms’ workloads for some OTC switches. Along with NDAs, sponsors would need to show a DFL isn’t sufficient to ensure a consumer can appropriately self-select and use a drug OTC and how an “additional condition” system would work.